康希諾AH股齊步走強 吸入用新冠疫苗臨牀試驗結果獲權威認可
格隆匯7月28日丨康希諾A股一度漲超10%報564.88元,H股一度漲近10%報286港元,最新市值1145億人民幣。7月26日,由中國工程院陳薇院士團隊和康希諾生物公司團隊合作研發的霧化吸入接種5型腺病毒載體新冠疫苗(Ad5-nCoV)在著名國際學術期刊《柳葉刀·傳染病》發表1期臨牀研究數據顯示,霧化吸入接種Ad5-nCoV具有良好的耐受性,未引起任何與疫苗相關的嚴重不良事件。一劑霧化Ad5-nCoV相當於單劑肌肉注射劑量的五分之一,霧化吸入接種兩劑Ad5-nCoV激發的新冠病毒中和抗體反應與肌肉注射一劑該疫苗相似。另一方面,肌肉注射Ad5-nCoV後第28天進行霧化吸入加強免疫,可誘導強烈的新冠病毒特異性IgG抗體和中和抗體反應。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.